XG0501

XG0501 (also known as Syn-001) is a replicating oncolytic adenovirus (recombinant human adenovirus type 5, rAd5) engineered to express the tumor suppressor gene **p53** (Tumor protein p53). Developed by **Beijing Syngentech**, the agent is designed to selectively replicate within and lyse cancer cells (oncolysis) while simultaneously delivering the p53 gene to restore apoptotic pathways in p53-deficient or mutated tumors. Unlike first-generation non-replicating p53 gene therapies, XG0501 is a next-generation replicating virus intended to enhance therapeutic efficacy through viral amplification within the tumor microenvironment. It is primarily being investigated for the treatment of advanced solid tumors, specifically **brain metastases from non-small cell lung cancer (NSCLC)**, where it is administered via local injection (e.g., intratumoral or intracerebral) in combination with standard therapies.

Other names

Ad-p53Ad-p-53Ad-p 53rAd-p53rAd-p-53rAd-p 53Recombinant human p53 adenovirusXG0501 injectionXG-0501 injectionXG 0501 injection